2021-08-01 16:14
publication
2021-08-01 16:14
–
–
US companies Pfizer and Moderna are raising prices of vaccines against COVID-19 in their latest contract with the European Union, thanks in part to the side effects of vaccines developed by competing pharmaceutical companies, the Financial Times reported on Sunday.
The agreement provides that by 2023 Pfizer and Moderna will supply the EU with up to 2.1 billion doses of vaccines. It was negotiated this year, when it turned out that the preparations of these companies are more effective in fighting the pandemic than the vaccines from Johnson & Johnson and AstraZeneca, according to the British daily.
The price of the Moderna vaccine under the contract will increase from $ 22.60 to $ 25.50. per dose, and the Pfizer preparation – from nearly $ 18.40 to $ 23.14. – reports “FT”, citing well informed sources.
On Wednesday, the Wall Street Journal reported that thanks to the sale of the COVID-19 vaccine and other drugs, Pfizer’s revenues for the second quarter of 2021 almost twice exceeded analysts’ forecasts. The vaccine alone has earned Pfizer $ 7.84 billion.
The American pharmaceutical giant forecasts that this year its revenues from the sale of this vaccine should reach $ 33.5 billion. assuming that the company delivers 2.1 billion doses to the market.
“FT” reports that the sale of the vaccine will bring Moderna $ 30 billion.
The European Commission announced that due to the possible need to administer a third dose of the COVID-19 vaccine, it reserves the right to supply an additional 1.8 billion doses of Pfizer.
On Tuesday, the European Commission announced that all indications are that 70 percent will be vaccinated by the end of summer. adult residents of the Union. (PAP)
fit/ akl/
–
